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Abstract Transthyretin (TTR) in plasma is associated with yel- 
low compounds. Their properties differ, and in the chicken protein 
a major yellow compound has recently been identified as a carot- 
enoid, lutein, also called xanthophyll. We now show that the 
major yellow component extracted from human TTR has proper- 
ties like a pterin derivative, 7,8-dihydropterin-6-carboxyaldehyde 
(2-amino-4-hydroxy-6-formyl-7,8-dihydropteridine). Th  human 
TTR derivative has chromatographic and spectral properties 
identical to a yellow photochemical degradation product of biop- 
terin and a spectrum like that of the pterin aldehyde. 
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1. Introduction 
Transthyretin (TTR) purified from different species is yel- 
lowish in colour and associated with several compounds [14]. 
The yellow compound has been elusive to determine, but can 
be isolated by methanol extraction. The extracted material con- 
stitutes a substantial part of the original protein, 2-6% [3]. It 
also contains fatty acids in appreciable amounts [4]. Recently, 
the yellow component extracted from chicken TTR was identi- 
fied as a carotenoid, lutein or xanthophyll [3]. It was then also 
noted that the major chicken compound was stable, in contrast 
to the unstable yellow component associated with human TTR. 
The absorbance spectra of the two yellow compounds were also 
quite different. We here provide evidence for a pterin nature 
of the major human yellow compound and suggest it to 
be 7,8-dihydropterin-6-carboxaldehyde (2-amino-4-hydroxy-6- 
formyl-7,8-dihydropteridine). 
2. Materials and methods 
2.1. Materials 
Serum was used as the source of human TTR. CNBr-activated 
Sepharose 4B, Sephadex G-25 and Sephaeryl S-200 were purchased 
from Pharmacia. Pterin, pterin-6-earboxylic acid and xanthopterin 
monohydrate were purchased from Aldrich, and biopterin, thyroxine 
(T4) and triodothyronine (T3) from Sigma. Solvents for the FPLC and 
HPLC systems were of HPLC grade from Merck. 
2.2. Protein purification 
Sepharose coupled with human retinol-binding protein was prepared 
as described and used for isolation of human TTR [5]. For exclusion 
of immunoglobulin contamination, the protein from this affinity 
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chromatography step was submitted to molecular exclusion chroma- 
tography on Sephacryl S-200 in 0.05 M phosphate buffer, 0.15 M NaCI, 
pH 7.4. 
2.3. Methanol extraction 
The protein was desalted on Sephadex G-25 fine and lyophilized. The 
purified TTR (30 mg) was boiled for 5-10 min in 15 ml acidic methanol. 
The suspended protein was centrifuged and the supernatant containing 
the yellow component collected. The extract was yellow and stored in 
methanol at -70°C. 
2.4. HPLC and FPLC 
The HPLC system utilized LKB 2248 pumps and a Pharmacia LKB 
controller. The methanol extract was fractionated on a semi-prepara- 
tive reverse-phase Clgcolumn (Nucleosil 5, 100 A., 250 x 10 mm; Scand. 
Gene Tech), using a 50-100% methanol gradient. The eluent was mon- 
itored at 280 and 430 nm and analyzed with a Schimadzu C-R5-A 
integrator. 
The material corresponding to the peaks obtained from the HPLC 
system was submitted to FPLC on a reverse-phase column Pep RPC 
515 HR (Pharmacia) with monitoring at 214 and 280 nm, utilizing two 
monitors UV-M. A gradient of 0-100% acetonitrile in0.1% TFA over 
20 min at a flow rate of 0.5 ml/min was used. 
A second HPLC system (Waters 625 LC), with a 991 Photodiode 
Array Detector (200-600 nm), allowing direct spectrophotometric anal- 
ysis of material corresponding to individual chromatographic peaks, 
was used for analysis of the purified yellow compound. 
3. Results 
3.1. HPLC and FPLC of the methanol extract of TTR 
The yellow material extracted from human TTR by acidic 
methanol was separated by reverse-phase chromatography. 
The first HPLC run (Fig. la) resulted in a number of fractions, 
the major fraction (A) being yellow. The preceding fraction, 
eluting after 18.9 ml, was rechromatographed in the same sys- 
tem, and separated into three fractions, AI-A3 (Fig. lb), A3 
having a retention volume corresponding to that of A in the 
previous chromatography. Fractions A1 and A3 both con- 
tained yellow component(s) as apparent by absorbance maxima 
at 430 nm. Material eluting later than A in the first HPLC 
separation was pooled from several preparations and rechro- 
matographed in the same system (Fig. lc), resulting in a num- 
ber of fractions (A-F). The collected material, corresponding 
to the different peaks, was fractionated further in an FPLC 
system on reverse-phase P p 515 (Fig. 2). The results how that 
fractions A1 and A3 both contain the same yellow compound 
(retention volume 19.7 ml), associated with hydrophobic mate- 
rial with retention volumes of 17.6 ml (fraction A1) and 15.4 
ml (fraction A3). The latter material was identified as thyrox- 
ine. The yellow component was finally analyzed by the second 
HPLC system (Fig. 3). 
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Fig. 1. Chromatographies of methanol extracts of human TTR. (a) 
HPLC on C~s (Nucleosil 5, 100 .~). Elution with a gradient of 80-100% 
methanol, 0-10 min, then 100% methanol, 3ml/min. The yellow mate- 
rial is recovered from fraction A as judged from the absorption spec- 
trum. (b) Material corresponding to the peak eluting at 18.9 ml in (a) 
was rechromatographed in the same system and a separation obtained 
(peak AI, A2 and A3). (c) Material eluting still later than fraction A 
in (a) was pooled from several chromatographies and rechromatogra- 
phed with a separation i to peaks A-F. 
3.2. Identification of thyrox&e 
In fractions A2 and B, major components were found to be 
thyroxine and triiodothyronine, respectively (Fig. 2). The 
minor material associated with the yellow component in frac- 
Fig. 2. FPLC on Pep 5/5 HR of different fractions (A1, A2, A3, B, C, 
D) from the HPLC system in Fig. 1. Isocratic elution with 6 ml 0.1% 
TFA in water, followed by a 0-100% acetonitrile gradient in 0.1% TFA, 
6 to 26 ml. (A1) Major fraction with retention volume 19.7 ml (indicated 
by Y), identified as the yellow compound by its absorbance maximum 
above 400 nm. The minor fraction at 17.6 ml is not identified, 2m,x 254, 
281 nm at pH 1; 262, 285, 328 nm at pH 9. (A2) Major fraction 
identified as thyroxine (T4). (A3) Major fraction at 19.7 ml (Y) is the 
yellow compound, the minor fraction at 15.4 ml is thyroxine (T4). (B) 
Major peak at 20.8 ml, not identified. The minor fraction at 14.7 ml is 
identified as triiodothyronine (T3). (C) Major peak at 21.8 ml, not 
identified. (D) Major peak at 24.0 ml, not identified. 
tion A3 was also identified as thyroxine. The identification was 
based on the characteristic spectra of the thyroid hormones at 
acidic and alkaline pH and on the chromatographic properties 
of commercial preparations of thyroxine and triiodothyronine 
being identical to those of the TTR-derived compounds. 
3.3. Properties of the yellow compound 
The crude methanol extract and the purified yellow com- 
pound were run analytically in a second HPLC system for 
analysis of the spectrum of the material corresponding to indi- 
vidual chromatographic peaks (Fig. 3). The yellow compound 
had a spectrum with absorbance maxima at 225, 271 and 436 
nm (100% acetonitrile, 0.1% TFA, pH 1; Fig. 3, bottom). In the 
FPLC system with Pep 5/5 (Fig. 2), the yellow compound was 
eluted with 69% acetonitrile. To elute the compound from the 
HPLC reverse-phase C~8 column, 100% acetonitrile was re- 
quired (gradient 50-100% acetonitrile, 0.1% TFA; Fig. 3), indi- 
cating that the yellow compound has a highly hydrophobic 
character. 
The purified yellow compound was sensitive to air and was 
not regained after lyophilization, but could be stored in 100% 
methanol at -70°C for more than 1 year. It was also possible 
to concentrate he yellow compound by evaporation of solvent 
with a blast of nitrogen. 
3.4. A pterin nature of the yellow component 
The absorbance spectrum of the yellow compound corre- 
sponds to published ata for the spectrum of an unstable hy- 
drophobic dihydropterin, 7 8-dihydropterin-6-carboxaldehyde. 
The material in different chromatographic fractions derived 
from our methanol extract was therefore lyophilized, resolved 
and oxidized with hydroperoxide. The resulting material was 
again lyophilized, resolved and rechromatographed in the 
FPLC system and tested for the presence of xanthopterin and 
pterin-6-carboxylic acid. In contrast o the very unstable 7,8- 
dihydro-pterin-6-carboxaldehyde, these compounds are stable 
and commercially available for comparison. The covalently 
hydrated form of xanthopterin was indeed chromatographi- 
cally detected after oxidation of some of the non-yellow mate- 
rial, indicating the possible presence of pterins other than the 
yellow component. 
3.5. Yellow degradation product of biopterin and dihydrofolate 
The yellow 7,8-dihydropterin-6-carboxaldehyde is known to 
be formed by photochemical degradation of biopterin and 
neopterin under anaerobic onditions and by oxidative degra- 
dation of dihydrofolate [6,7]. 
To obtain further evidence for the character of the TTR- 
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Fig. 3. Chromatographic analysis of the yellow methanol extract obtained from human TTR. Analysis by a Waters 625 Inert Gradient System with 
a 994 Photodiode Array Detector. Gradient 50-100% acetonitrile in0.1% TFA for 0-10 rain, flow rate 1 ml/min. The only peak (Y) with absorbance 
maximum above 400 nm eluted after 10.2 ml. Chromatograms onitored at 280 and 435 nm (top) and absorbance spectrum of the yellow compound 
(bottom) are shown. 
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Fig. 4. FPLC of material resulting from exposure of biopterin i  acidic 
methanol to light for 2 weeks under anaerobic conditions. Column: Pep 
5/5 HR as in Fig. 2. In the chromatogram the first large peak represents 
intact biopterin, the peak at 16.4 ml probably xanthopterin in its cova- 
lent hydrated form, and the peak at 19.6 ml a yellow compound (Y), 
probably 7,8-dihydropterin-6-carboxaldehyde, known to be formed by 
photodegradation of biopterin. The yellow fraction was collected, im- 
mediately bubbled with nitrogen, and analyzed with a spectrophotom- 
eter for a rough spectrum (bottom). 
associated yellow compound, commercial biopterin was dis- 
solved in methanol acidified with hydrochloric acid, bubbled 
with nitrogen, closed, and left in a glass tube submitted to 
sunshine. This procedure repeatedly resulted in brown-red 
products, some of which precipitated in the tubes. The spectra 
of these products indicate that they may correspond to 5,8- 
dihydropterin-6-carboxaldehyde an  5,8-dihydropterin-7-car- 
boxaldehyde [8,9], which on exposure to oxygen are spontane- 
ously dehydrogenated to the corresponding pterin-aldehydes 
[10], further oxidation yielding pterin-carboxylic acids [9]. 
However, one of our photodegradation attempts, with bright 
sunshine for 2 weeks, resulted in a clear yellow colour of the 
originally uncoloured biopterin solution. This photodegraded 
biopterin was chromatographed and the yellow pterin identi- 
fied in the FPLC and HPLC systems. The chromatographic 
behaviour and the spectrogram was identical to those of the 
yellow compound associated with human TTR (cf. chromato- 
grams in Figs. 2C and 4 and spectra in Figs. 3 and 4). Of the 
different yellow pterin compounds, the spectrum is in best 
agreement with that of 7,8-dihydropterin-6-carboxaldehyde 
[11,12]. 
4. Discussion 
4.1. Origin of the major yellow compound 
Our results confirm that hydrophobic compounds extracta- 
ble with methanol are associated with human TTR. In contrast 
to the situation with chicken TTR, no component with a spec- 
trum with three strong absorbance maxima in the 400-550 nm 
region, chacteristic of most carotenoids, has been found. Also, 
in contrast to the yellow fraction associated with chicken TTR, 
the one extracted from human TTR is highly unstable in its 
chromatographically pure form and is rapidly degraded to un- 
coloured compounds when exposed to air. Comparison with 
the yellow product from photochemical degradation of com- 
mercial biopterin shows that the yellow compound associated 
with human TTR is a pterin, probably 7,8-dihydropterin-6- 
carboxaldehyde. This unstable aldehyde is apparently derived 
from a more stable pterin during the preparation of TTR from 
human serum. Native TTR is only slightly yellow and a strong 
colour does not appear until boiling in acidic methanol. It may 
also be noted that amyloid TTR is distinctly ellow and that 
the yellow compound in that case is extractable with neutral 
methanol without boiling, indicating that it is preformed and 
not the result of the preparative procedure. Spectra of material 
in individual chromatographic peaks were now obtained with 
a diode array detector on line, which is a great advantage with 
unstable compounds. A tentative conclusion is that human 
plasma TTR is associated with either a reduced pterin or a 
folate, which during preparation of TTR is degraded, resulting 
in the formation of the yellow compound 7,8-dihydropterin-6- 
carboxaldehyde. 
4.2. Possible functional implications 
Tetrahydrobiopterin has been suggested to be a cofactor in 
the deiodination of thyroxine, though shown not to be required 
as a cofactor to the cellular 5'-deiodinase [13]. It is more prob- 
able that reduced pterins may have a protective role against 
superoxide radicals, thus a role similar to that for the carote- 
noids [14]. 
4.3. Transthyretin and the choroid plexus 
TTR is a major protein synthesized and secreted by the 
choroid plexus in reptiles, birds and mammals [15]. This TTR 
is relevant for the transport of thyroxine into the cerebrospinal 
fluid [16]. TTR might also be important as a carrier of folates 
into the brain after absorption of the folates through the action 
of the glycosylphosphatidylinositol-anchored folate receptor 
on the epithelial cells of the choroid plexus [17]. 
4.4. Transthyretin and hydrophobic ompounds 
Recent research as shown that different hydrophobic com- 
pounds, such as the yellow pterin derivative (this work), the 
carotenoid lutein [3], and also fatty acids [4], may be associated 
with TTR from different species. This suggests that TTR may 
have a hydrophobic left into which these compounds bind. 
However, some specificity must exist as chicken and human 
TTRs appear to be associated with different compounds, and 
in the chicken protein apparently with lutein only, but not with 
other carotenoids. 
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